Illumina Presses $113.3M Bid For DNA Sequencer

Law360, New York (November 21, 2012, 2:30 PM EST) -- Illumina Inc., the gene-sequencing company that successfully fended off a hostile takeover earlier this year from pharmaceutical giant Roche AG, is now involved in a battle of its own after biotech firm Complete Genomics Inc. rejected its $113.3 million takeover offer Wednesday.

Illumina’s $3.30 per-share offer is about 5 percent higher than a rival bid from BGI-Shenzhen, the operator of Chinese DNA analysis centers that agreed to buy Complete Genomics in September. The would-be buyer said its takeover was more likely to close and have fewer...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.